PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2906798-6 1988 The specific D2-receptor blockers haloperidol and molindone, completely blocked the stereotypic responses due to B-HT 920 and apomorphine. Haloperidol 34-45 dopamine receptor D2 Mus musculus 13-24 2522303-3 1989 We investigated the effects of 6-week continuous nicotine intake on the neuroleptic (haloperidol)-induced increase in murine striatal D2-dopamine receptor density. Haloperidol 85-96 dopamine receptor D2 Mus musculus 134-154 3037094-4 1987 Chronic haloperidol treatment increased striatal D2 dopamine receptor density by 25% but had no effect on membrane-bound calmodulin levels. Haloperidol 8-19 dopamine receptor D2 Mus musculus 49-69 33645311-9 2021 The dopamine D2 receptor (D2) antagonist haloperidol administered after LSD increased burst-firing activity in the reticular thalamus neurons inhibited by LSD, decreased firing and burst-firing activity in the mediodorsal thalamus, and showed a trend towards further increasing the firing activity of neurons of the infralimbic prefrontal cortex. Haloperidol 41-52 dopamine receptor D2 Mus musculus 4-24 2950056-2 1986 Pretreatment with haloperidol, an antagonist of both D-1 and D-2 dopamine receptors, metoclopramide and molindone, the selective D-2 dopamine receptor antagonists, effectively antagonised bromocriptine-induced climbing behaviour. Haloperidol 18-29 dopamine receptor D2 Mus musculus 61-82 2423865-0 1986 Haloperidol binding to monoclonal antibodies: conformational analysis and relationships to D-2 receptor binding. Haloperidol 0-11 dopamine receptor D2 Mus musculus 91-103 2423865-6 1986 Inhibition of [3H]haloperidol binding to mAb A by 16 unlabeled haloperidol analogs displayed a good correlation [r = 0.82, n = 16, m = 1.06(+/- 0.38)] with D-2 receptor binding affinity, suggesting that the parts of the D-2 receptor combining site which recognize butyrophenone antagonists may have molecular characteristics which are similar to those of the monoclonal antibody. Haloperidol 18-29 dopamine receptor D2 Mus musculus 156-168 2423865-6 1986 Inhibition of [3H]haloperidol binding to mAb A by 16 unlabeled haloperidol analogs displayed a good correlation [r = 0.82, n = 16, m = 1.06(+/- 0.38)] with D-2 receptor binding affinity, suggesting that the parts of the D-2 receptor combining site which recognize butyrophenone antagonists may have molecular characteristics which are similar to those of the monoclonal antibody. Haloperidol 18-29 dopamine receptor D2 Mus musculus 220-232 2423865-6 1986 Inhibition of [3H]haloperidol binding to mAb A by 16 unlabeled haloperidol analogs displayed a good correlation [r = 0.82, n = 16, m = 1.06(+/- 0.38)] with D-2 receptor binding affinity, suggesting that the parts of the D-2 receptor combining site which recognize butyrophenone antagonists may have molecular characteristics which are similar to those of the monoclonal antibody. Haloperidol 63-74 dopamine receptor D2 Mus musculus 156-168 2423865-6 1986 Inhibition of [3H]haloperidol binding to mAb A by 16 unlabeled haloperidol analogs displayed a good correlation [r = 0.82, n = 16, m = 1.06(+/- 0.38)] with D-2 receptor binding affinity, suggesting that the parts of the D-2 receptor combining site which recognize butyrophenone antagonists may have molecular characteristics which are similar to those of the monoclonal antibody. Haloperidol 63-74 dopamine receptor D2 Mus musculus 220-232 32919985-10 2020 Haloperidol (0.05 mg/kg, i.p) was used to antagonize the effects of D2/D3 receptor activation. Haloperidol 0-11 dopamine receptor D2 Mus musculus 68-82 33479510-7 2022 Remarkably, a number of these behavioral deficits could be rescued by the administration of mu-opioid and D2 dopamine receptor (D2R) antagonists: naltrexone and haloperidol, respectively, suggesting that loss of neuropsychiatric manifestations in mice lacking GPR139 are driven by opioidergic and dopaminergic hyper-functionality. Haloperidol 161-172 dopamine receptor D2 Mus musculus 106-126 33479510-7 2022 Remarkably, a number of these behavioral deficits could be rescued by the administration of mu-opioid and D2 dopamine receptor (D2R) antagonists: naltrexone and haloperidol, respectively, suggesting that loss of neuropsychiatric manifestations in mice lacking GPR139 are driven by opioidergic and dopaminergic hyper-functionality. Haloperidol 161-172 dopamine receptor D2 Mus musculus 128-131 33009372-3 2020 Here, we have identified that the depletion of the mTOR gene in the mice striatum completely prevented the extrapyramidal motor side effects (catalepsy) induced by the dopamine 2 receptor (D2R) antagonist haloperidol, which is the most widely used typical antipsychotic drug. Haloperidol 205-216 dopamine receptor D2 Mus musculus 168-187 33009372-3 2020 Here, we have identified that the depletion of the mTOR gene in the mice striatum completely prevented the extrapyramidal motor side effects (catalepsy) induced by the dopamine 2 receptor (D2R) antagonist haloperidol, which is the most widely used typical antipsychotic drug. Haloperidol 205-216 dopamine receptor D2 Mus musculus 189-192 33009372-8 2020 Collectively, our data indicate that striatal mTORC1 blockade may offer therapeutic benefits with regard to the prevention of D2R-dependent extrapyramidal motor side effects of haloperidol in psychiatric illness. Haloperidol 177-188 dopamine receptor D2 Mus musculus 126-129 29209205-7 2017 The combined effect of propranolol and morphine was attenuated by haloperidol (D2 receptor antagonist, 1.5 mg/Kg, IP), and bicuculline (GABAA receptor antagonist, 2 mg/Kg, IP). Haloperidol 66-77 dopamine receptor D2 Mus musculus 79-90 32175760-12 2020 We tested the effect of the dopamine D2 receptor antagonist, haloperidol, on performance in the CEC and CVC assays and found that D2R signaling is important for effort-based, but not value-based decision making. Haloperidol 61-72 dopamine receptor D2 Mus musculus 28-48 30417675-3 2020 exhibited markedly antidepressant-like activity, which could be reversed by pretreatment with haloperidol (a non-selective D2 receptor antagonist), bicuculline (a competitive GABA antagonist), p-chlorophenylalanine (an inhibitor of 5-HT synthesis). Haloperidol 94-105 dopamine receptor D2 Mus musculus 123-134 31233824-3 2019 Following acute PCP administration to mice, the content of miRNA-143 was reduced in plasma, prefrontal cortex (PFC) and hippocampus, reaching a minimum after 2 h. The antipsychotics haloperidol and clozapine attenuated hyperlocomotion and the decrease in miR-143 expression induced by PCP, as did the selective D2 dopamine receptor antagonist eticlopride but not the selective D1 antagonist SCH23390. Haloperidol 182-193 dopamine receptor D2 Mus musculus 311-331 30597182-0 2019 Aripiprazole and haloperidol protect neurite lesions via reducing excessive D2R-DISC1 complex formation. Haloperidol 17-28 dopamine receptor D2 Mus musculus 76-79 28186680-0 2017 The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. Haloperidol 93-104 dopamine receptor D2 Mus musculus 70-81 28017790-10 2017 However we observed a decreased response to the dopamine D2 receptor antagonist haloperidol only in hypothyroid CB1R+/+ mice, which might indicate potential alterations in D2R signaling in these animals. Haloperidol 80-91 dopamine receptor D2 Mus musculus 48-68 20406627-4 2010 was prevented by the pretreatment of mice with haloperidol (0.2mg/kg, i.p., a nonselective dopaminergic receptor antagonist), SCH23390 (0.05 mg/kg, s.c., a selective dopamine D1 receptor antagonist), and sulpiride (50mg/kg, i.p., a selective dopamine D2 receptor antagonist). Haloperidol 47-58 dopamine receptor D2 Mus musculus 242-262 27578530-11 2016 RNA interference knockdown of DRD2 or inhibition with pharmacologic antagonists (pimozide and haloperidol) reduced proliferation of pancreatic cancer cells, induced endoplasmic reticulum stress and apoptosis, and reduced cell migration. Haloperidol 94-105 dopamine receptor D2 Mus musculus 30-34 27578530-12 2016 RNA interference knockdown of DRD2 in pancreatic tumor cells reduced growth of xenograft tumors in mice, and administration of the DRD2 inhibitor haloperidol to mice with orthotopic xenograft tumors reduced final tumor size and metastasis. Haloperidol 146-157 dopamine receptor D2 Mus musculus 131-135 27480797-12 2016 The effects of haloperidol are mimicked and occluded by a D2 receptor antagonist in slices from PGC-1alpha+/+ mice, and the effects of blocking D2 receptors are lost in slices from PGC-1alpha-/- mice, although there is no change in D2 receptor transcript levels. Haloperidol 15-26 dopamine receptor D2 Mus musculus 58-69 27435383-1 2016 Haloperidol is an antipsychotic drug that inhibits the dopamine D2 receptor among others. Haloperidol 0-11 dopamine receptor D2 Mus musculus 55-75 26842661-10 2016 CONCLUSIONS The data strongly suggest that haloperidol inhibits the immune response by suppressing NF-kB signaling via the dopamine D2 receptor. Haloperidol 43-54 dopamine receptor D2 Mus musculus 123-143 24747358-8 2014 Gpr6(-/-) mice showed higher locomotor activity in the open field, which persisted after treatment with the dopamine D2 receptor antagonist haloperidol. Haloperidol 140-151 dopamine receptor D2 Mus musculus 108-128 21603181-5 2011 Subsequently DIO mice were treated with the DRD2 agonist bromocriptine and DR mice with the DRD2 antagonist haloperidol for 2 weeks. Haloperidol 108-119 dopamine receptor D2 Mus musculus 92-96 26706182-1 2016 Blockade of dopamine D2 receptor by haloperidol is attributed for neuroleptic and cataleptic effects; and also for the release of gonadotropin releasing hormone (GnRH) from the hypothalamus. Haloperidol 36-47 dopamine receptor D2 Mus musculus 12-32 26658842-7 2015 Interestingly, these temporal association and working memory deficits could be mimicked by a low dose of the dopamine D2 receptor antagonist haloperidol. Haloperidol 141-152 dopamine receptor D2 Mus musculus 109-129 25826871-2 2015 SCH-23390 (1.0 mg/kg), selective antagonist of dopamine D1 receptors, and selective D2 receptor blocker haloperidol (1 mg/kg) prevented the immunostimulating effect of DPDPE in animals not subjected to social stress. Haloperidol 104-115 dopamine receptor D2 Mus musculus 84-95 25122042-0 2014 Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: do antipsychotics influence learning to ignore irrelevant stimuli via both Drd-2 and non-Drd-2 mechanisms? Haloperidol 37-48 dopamine receptor D2 Mus musculus 80-100 25122042-0 2014 Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: do antipsychotics influence learning to ignore irrelevant stimuli via both Drd-2 and non-Drd-2 mechanisms? Haloperidol 37-48 dopamine receptor D2 Mus musculus 102-107 25122042-0 2014 Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: do antipsychotics influence learning to ignore irrelevant stimuli via both Drd-2 and non-Drd-2 mechanisms? Haloperidol 37-48 dopamine receptor D2 Mus musculus 200-205 25122042-0 2014 Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2)-deficient mice: do antipsychotics influence learning to ignore irrelevant stimuli via both Drd-2 and non-Drd-2 mechanisms? Haloperidol 37-48 dopamine receptor D2 Mus musculus 200-205 24658464-6 2014 Importantly, glioblastoma lines derived from independent genetically engineered mouse models (GEMMs) were more sensitive to haloperidol, an FDA approved DRD2 antagonist, than the premalignant astrocyte lines by approximately an order of magnitude. Haloperidol 124-135 dopamine receptor D2 Mus musculus 153-157 24552586-3 2014 This was based upon our finding that the low D2 receptor affinity APD clozapine induced initial down-regulation and delayed epidermal growth factor receptor (EGFR or ErbB1) mediated activation of the cortical and striatal ERK response in vivo distinct from olanzapine or haloperidol. Haloperidol 271-282 dopamine receptor D2 Mus musculus 45-56 23748226-6 2013 This effect was fully antagonized by acute treatment with the preferential dopamine D2 receptor antagonist haloperidol, but not with clozapine. Haloperidol 107-118 dopamine receptor D2 Mus musculus 75-95 23422792-10 2013 Remarkably, both haloperidol and clozapine attenuated AMP disruption of LI in Drd2-/-. Haloperidol 17-28 dopamine receptor D2 Mus musculus 78-82 23385580-7 2013 Microinjection of ghrelin or XE991 into substantia nigra pars compacta results in contralateral dystonic posturing, and attenuation of catalepsy elicited by systemic administration of the D2 receptor antagonist haloperidol. Haloperidol 211-222 dopamine receptor D2 Mus musculus 188-199 22561101-4 2012 We show that both D1R agonist A-68930 and dopamine receptor D2 antagonist haloperidol can decrease [(3)H]MK-801 binding with increased potency in membranes from the NR2A(-/-) mice (i.e. in membranes containing NR2B only), as compared to the inhibition obtained in wild-type membranes. Haloperidol 74-85 dopamine receptor D2 Mus musculus 42-62 21062378-6 2011 intake while they were treated with the DRD2 antagonist haloperidol or vehicle using s.c. implanted pellets. Haloperidol 56-67 dopamine receptor D2 Mus musculus 40-44 20618446-6 2010 The D(2) receptor antagonist haloperidol reversed the hyperactivity, PPI and latent inhibition (LI) deficits and blocked the psychostimulant effect of amphetamine in DISC1-L100P mutants. Haloperidol 29-40 dopamine receptor D2 Mus musculus 4-17 20720111-9 2010 Such biochemical alteration selectively affected dopamine D(1)Rs since haloperidol, by blocking the tonic inhibition of D(2)R, unmasked a normal activation of striatal adenosine A(2A) receptor-mediated cAMP/PKA/DARPP32 cascade in mutants. Haloperidol 71-82 dopamine receptor D2 Mus musculus 120-125 20808911-9 2010 The Comt variant causes downstream differences in the expression of genes involved in synaptic function, and also modulates phenotypes such as dopamine D1 and D2 receptor binding and pharmacological responses to haloperidol. Haloperidol 212-223 dopamine receptor D2 Mus musculus 159-170 18690109-5 2008 In Balb/c mice, the effect of 8-OH-DPAT was blocked by the typical antipsychotic and dopamine D2 receptor antagonist, haloperidol and the third generation antipsychotic, aripiprazole, which has activity at both 5-HT1A and dopamine D2 receptors. Haloperidol 118-129 dopamine receptor D2 Mus musculus 85-105 19963037-11 2010 This enhancement was inhibited by a dopamine D(2) receptor antagonist, haloperidol (0.1mg/kg, s.c.). Haloperidol 71-82 dopamine receptor D2 Mus musculus 36-58 17035544-4 2006 Treatment with haloperidol, a D2 dopamine receptor antagonist, reduces this abnormal intrusion of REM-like activity during wakefulness. Haloperidol 15-26 dopamine receptor D2 Mus musculus 30-50 17696993-5 2008 They showed impaired prepulse inhibition of acoustic startle response, which was ameliorated by a systemic administration of an antipsychotic D2-receptor antagonist, haloperidol. Haloperidol 166-177 dopamine receptor D2 Mus musculus 142-153 16893530-6 2006 Dopamine turnover disturbances are also found after acute challenge with haloperidol, a dopamine D2 receptor antagonist. Haloperidol 73-84 dopamine receptor D2 Mus musculus 88-108 18509028-0 2008 Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. Haloperidol 128-139 dopamine receptor D2 Mus musculus 61-72 18332675-4 2008 Although haloperidol (dopamine D2-receptor antagonist) did not affect SNC80-induced hyperactivity, it inhibited morphine-induced hyperlocomotion. Haloperidol 9-20 dopamine receptor D2 Mus musculus 22-42 17097724-14 2006 Since both haloperidol and the atypical drugs increased PPI, it is likely that D2 dopamine receptor blockade is responsible for the drug effects on sensorimotor gating. Haloperidol 11-22 dopamine receptor D2 Mus musculus 79-99 16904653-3 2006 More specifically, we induced stress-associated hypofunction of dopaminergic, mainly D2 dopamine receptor-mediated neurotransmission by haloperidol and explored stress induced hyperlocomotion and catalepsy, an extreme form of immobility, induced in mice with AChE deficiencies. Haloperidol 136-147 dopamine receptor D2 Mus musculus 85-105 17029599-1 2006 Haloperidol, a dopamine D2 receptor blocker, is a classical neuroleptic drug that elicits extrapyramidal symptoms. Haloperidol 0-11 dopamine receptor D2 Mus musculus 15-35 16284244-8 2005 This deficit was completely normalized by treatment with the antipsychotic D2-receptor antagonist haloperidol. Haloperidol 98-109 dopamine receptor D2 Mus musculus 75-86 16563475-6 2006 Further, the ribavirin induced antinociception was enhanced by D2 receptor antagonists haloperidol, sulpiride, clozapine or domperidone and by the dopamine D2 receptor agonist bromocryptine. Haloperidol 87-98 dopamine receptor D2 Mus musculus 63-74 16336634-5 2006 Administration of haloperidol, an antipsychotic drug with dopamine D2 receptor antagonistic properties, increases the phosphorylation of GluR1 at Ser845, without affecting phosphorylation at Ser831. Haloperidol 18-29 dopamine receptor D2 Mus musculus 58-78 16407246-4 2006 Expression of the striatal dopamine D(2) receptor, the main site of haloperidol action, did not differ between the two genotypes. Haloperidol 68-79 dopamine receptor D2 Mus musculus 27-49 16407246-7 2006 Based on these findings, we proposed a new molecular mechanism underlying haloperidol-induced catalepsy, in which the dopamine D(2) receptor antagonist induces striatal Fyn activation and the subsequent tyrosine phosphorylation of NR2B alters striatal neuronal activity, thereby inducing the behavioral changes that are manifested as a cataleptic response. Haloperidol 74-85 dopamine receptor D2 Mus musculus 118-140 15305880-2 2004 Here we show that the increases in TH phosphorylation produced by haloperidol at Ser31 and Ser40, two sites critically involved in the regulation of enzymatic activity, are abolished in dopamine D2 receptor-null mice and mimicked by the selective dopamine D2 receptor antagonist, eticlopride. Haloperidol 66-77 dopamine receptor D2 Mus musculus 186-206 15817666-4 2005 In wild-type mice, prolonged treatment with the D2R antagonist, haloperidol, enhanced pituitary VEGF expression and prolactin release, suggesting that dopamine inhibits pituitary VEGF expression. Haloperidol 64-75 dopamine receptor D2 Mus musculus 48-51 15305880-2 2004 Here we show that the increases in TH phosphorylation produced by haloperidol at Ser31 and Ser40, two sites critically involved in the regulation of enzymatic activity, are abolished in dopamine D2 receptor-null mice and mimicked by the selective dopamine D2 receptor antagonist, eticlopride. Haloperidol 66-77 dopamine receptor D2 Mus musculus 247-267 11522598-17 2001 Administration of the dopamine D2 receptor antagonist haloperidol (50 - 200 microg kg(-1) i.p.) Haloperidol 54-65 dopamine receptor D2 Mus musculus 22-42 12767400-0 2003 Sigma1 and dopamine D2 receptor occupancy in the mouse brain after a single administration of haloperidol and two dopamine D2-like receptor ligands. Haloperidol 94-105 dopamine receptor D2 Mus musculus 11-31 15140647-1 2004 The increase of Fos expression in the striatum induced by haloperidol, an antagonist of the dopamine D2 receptor, might be related to the activation of glutamatergic neurotransmission, especially that of N-methyl-D-aspartate (NMDA) receptors. Haloperidol 58-69 dopamine receptor D2 Mus musculus 92-112 15001689-11 2004 Intraperitoneal injection of the unlabeled D(2) receptor antagonist haloperidol 30 min before intravenous injection of (18)F-fallypride blocked tracer accumulation in the striatum by >95%. Haloperidol 68-79 dopamine receptor D2 Mus musculus 43-56 14663017-6 2003 In support of this idea, administration of the dopamine D2 receptor antagonist haloperidol prevented antidepressant-like effects elicited by SCH 58261 in the forced swim test (putatively involving cortex), whereas it had no effect on stimulant motor effects of SCH 58261 (putatively linked to ventral striatum). Haloperidol 79-90 dopamine receptor D2 Mus musculus 47-67 12941370-4 2003 LY366457-induced hyperactivity was significantly attenuated by the selective D1 dopamine receptor antagonist SCH23390 and also by the D2 dopamine receptor antagonist haloperidol but only at doses that significantly suppressed spontaneous locomotion. Haloperidol 166-177 dopamine receptor D2 Mus musculus 134-154 11504791-5 2001 After repeated administration, the increase in D(2) receptor mRNA levels in mice treated with haloperidol at 9:00 AM was higher than that of mice treated with haloperidol at 9:00 PM. Haloperidol 94-105 dopamine receptor D2 Mus musculus 47-60 11504791-5 2001 After repeated administration, the increase in D(2) receptor mRNA levels in mice treated with haloperidol at 9:00 AM was higher than that of mice treated with haloperidol at 9:00 PM. Haloperidol 159-170 dopamine receptor D2 Mus musculus 47-60 11313158-12 2001 These results demonstrate that NOS inhibitors as well as dopamine D(2) receptor antagonist haloperidol can induce motor deficit in mice. Haloperidol 91-102 dopamine receptor D2 Mus musculus 57-79 7628827-2 1995 The analgesic effect induced by 0.25 mg/kg RU 24926 was dose dependently antagonized by the preferential D2 dopamine receptor antagonist haloperidol (ID50 = 15.1 +/- 3.3 micrograms/kg sc) as well as by the opioid receptor antagonist naloxone (ID50 = 0.59 +/- 0.17 mg/kg sc). Haloperidol 137-148 dopamine receptor D2 Mus musculus 105-125 10891603-3 2000 Moreover, pretreatment with either naloxone (an opioid receptor antagonist) or haloperidol (a mixed D(1)/D(2) receptor antagonist) eliminated the enhancement by morphine of climbing behavior in wild type mice. Haloperidol 79-90 dopamine receptor D2 Mus musculus 105-118 10102770-3 1999 Unlike olanzapine, the selective dopamine D2 receptor antagonists such as haloperidol (0.25 and 0.5 mg/kg) and pimozide (0.5 and 1 mg/kg), the selective 5-HT2A receptor antagonist, ritanserin (0.5 and 1 mg/kg) or the antimuscarinic agent scopolamine (0.5 and 1 mg/kg) failed to produce any locomotor stimulant effect. Haloperidol 74-85 dopamine receptor D2 Mus musculus 33-53 8728542-1 1996 Differences in the behavioural profiles of dopamine D2 receptor antagonists (e.g., haloperidol vs. sulpiride) in a animal models of anxiety have prompted speculation concerning the importance of their relative affinities for D2-like receptor populations. Haloperidol 83-94 dopamine receptor D2 Mus musculus 43-63 8728563-3 1996 The D2 dopamine receptor antagonist haloperidol dose dependently (12.5-50 micrograms/kg i.p.) Haloperidol 36-47 dopamine receptor D2 Mus musculus 4-24 8998404-4 1995 The preferential D2 dopamine receptor antagonist haloperidol 37.5-150 micrograms/kg i.p. Haloperidol 49-60 dopamine receptor D2 Mus musculus 17-37 8577369-3 1995 Haloperidol, a preferential D2 receptor antagonist, completely blocked this [Ca2+]i response to quinpirole. Haloperidol 0-11 dopamine receptor D2 Mus musculus 28-39 10940355-1 2000 We previously reported that following acute administration of haloperidol or (-)-sulpiride, both dopamine D(2)-receptor antagonists, to mice induced nerve growth factor (NGF) gene expression, mediated by the interaction of c-fos with the AP-1 binding site present in the first intron on the NGF gene. Haloperidol 62-73 dopamine receptor D2 Mus musculus 97-119 9618422-1 1998 Long-term inhibition of D2 dopamine receptors using classic D2 dopamine receptor antagonists such as haloperidol often causes a compensatory up-regulation of the D2 dopamine receptors. Haloperidol 101-112 dopamine receptor D2 Mus musculus 24-44 9682282-24 1998 These results also provide evidence that D2 receptor antagonists may be more effective as antipsychotic drugs than dopamine D1 receptor antagonist, since the coadministration of haloperidol with cocaine normalized the abnormal behaviors seen during early and long-term withdrawal periods from chronic cocaine. Haloperidol 178-189 dopamine receptor D2 Mus musculus 41-52 8962158-4 1996 By contrast, haloperidol, a typical neuroleptic that acts preferentially at D2-class receptors, remains effective in inducing catalepsy and striatal Fos/Jun expression in the D1 mutants, and these behavioral and neural effects can be blocked by D2 dopamine receptor agonists. Haloperidol 13-24 dopamine receptor D2 Mus musculus 245-265 7895775-7 1994 In these mice, treatment with the dopamine D2 receptor antagonist haloperidol led to a 28% reduction in the absolute amount of ethanol consumed, but not in voluntary ethanol preference. Haloperidol 66-77 dopamine receptor D2 Mus musculus 34-54 31034808-3 2019 Dopamine D2 receptor (D2R) blockers such as haloperidol are mainstays in the treatment of psychosis but may contribute to the development of secondary acute and tardive dystonia. Haloperidol 44-55 dopamine receptor D2 Mus musculus 0-20 1705651-0 1991 Haloperidol treatment increases D2 dopamine receptor protein independently of RNA levels in mice. Haloperidol 0-11 dopamine receptor D2 Mus musculus 32-52 1705651-1 1991 Haloperidol, administered to mice in their drinking water, produced a 21% increase in striatal D2 dopamine receptor density after seven days of continuous exposure. Haloperidol 0-11 dopamine receptor D2 Mus musculus 95-115 10720636-6 2000 The degree of haloperidol-induced catalepsy was thus proportional to the level of striatal dopamine D(2) receptor expression (0.50, 0.30 and 0.08 pmol/mg protein as measured at 0.25 nM [3H]spiperone for D(2)(+/+), D(2)(+/-) and D(2)(-/-) mice, respectively). Haloperidol 14-25 dopamine receptor D2 Mus musculus 91-113 10720636-13 2000 These results suggest that the dopamine D(2) receptor subtype is necessary for haloperidol to produce catalepsy, and that the dopamine D(3) receptor subtype appears to exert no observable control over the catalepsy produced by dopamine D(2)-like, D(1)-like and the combination of D(1)-like and D(2)-like receptor antagonists. Haloperidol 79-90 dopamine receptor D2 Mus musculus 31-53 34216648-7 2021 However, amantadine"s effect was blocked by the dopamine D2 receptor antagonist haloperidol and glutamate receptor agonist N-methyl-D-aspartate (NMDA). Haloperidol 80-91 dopamine receptor D2 Mus musculus 48-68